Logo image of IBRX

IMMUNITYBIO INC (IBRX) Stock Fundamental Analysis

NASDAQ:IBRX - Nasdaq - US45256X1037 - Common Stock - Currency: USD

2.82  +0.35 (+14.17%)

After market: 2.79 -0.03 (-1.06%)

Fundamental Rating

3

Taking everything into account, IBRX scores 3 out of 10 in our fundamental rating. IBRX was compared to 550 industry peers in the Biotechnology industry. Both the profitability and financial health of IBRX have multiple concerns. IBRX shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IBRX had negative earnings in the past year.
IBRX had a negative operating cash flow in the past year.
In the past 5 years IBRX always reported negative net income.
In the past 5 years IBRX always reported negative operating cash flow.
IBRX Yearly Net Income VS EBIT VS OCF VS FCFIBRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M -500M

1.2 Ratios

IBRX's Return On Assets of -134.68% is on the low side compared to the rest of the industry. IBRX is outperformed by 83.09% of its industry peers.
Industry RankSector Rank
ROA -134.68%
ROE N/A
ROIC N/A
ROA(3y)-112.85%
ROA(5y)-102.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBRX Yearly ROA, ROE, ROICIBRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100

1.3 Margins

The Gross Margin of IBRX (47.23%) is better than 75.82% of its industry peers.
IBRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.23%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBRX Yearly Profit, Operating, Gross MarginsIBRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K

More info and screens

2

2. Health

2.1 Basic Checks

IBRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IBRX has more shares outstanding
IBRX has more shares outstanding than it did 5 years ago.
IBRX has a worse debt/assets ratio than last year.
IBRX Yearly Shares OutstandingIBRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
IBRX Yearly Total Debt VS Total AssetsIBRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

IBRX has an Altman-Z score of -17.76. This is a bad value and indicates that IBRX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -17.76, IBRX is not doing good in the industry: 82.55% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -17.76
ROIC/WACCN/A
WACC10.71%
IBRX Yearly LT Debt VS Equity VS FCFIBRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

2.3 Liquidity

IBRX has a Current Ratio of 2.22. This indicates that IBRX is financially healthy and has no problem in meeting its short term obligations.
IBRX has a Current ratio of 2.22. This is in the lower half of the industry: IBRX underperforms 74.00% of its industry peers.
A Quick Ratio of 2.05 indicates that IBRX has no problem at all paying its short term obligations.
IBRX has a Quick ratio of 2.05. This is in the lower half of the industry: IBRX underperforms 72.55% of its industry peers.
Industry RankSector Rank
Current Ratio 2.22
Quick Ratio 2.05
IBRX Yearly Current Assets VS Current LiabilitesIBRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 51.06% over the past year.
Looking at the last year, IBRX shows a very strong growth in Revenue. The Revenue has grown by 2270.58%.
Measured over the past years, IBRX shows a very strong growth in Revenue. The Revenue has been growing by 46.30% on average per year.
EPS 1Y (TTM)51.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)2270.58%
Revenue growth 3Y151.22%
Revenue growth 5Y46.3%
Sales Q2Q%2423.88%

3.2 Future

Based on estimates for the next years, IBRX will show a very strong growth in Earnings Per Share. The EPS will grow by 38.62% on average per year.
The Revenue is expected to grow by 140.93% on average over the next years. This is a very strong growth
EPS Next Y21.08%
EPS Next 2Y21.38%
EPS Next 3Y32.02%
EPS Next 5Y38.62%
Revenue Next Year543.75%
Revenue Next 2Y309.55%
Revenue Next 3Y288.49%
Revenue Next 5Y140.93%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBRX Yearly Revenue VS EstimatesIBRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B 2.5B
IBRX Yearly EPS VS EstimatesIBRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IBRX. In the last year negative earnings were reported.
Also next year IBRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBRX Price Earnings VS Forward Price EarningsIBRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBRX Per share dataIBRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as IBRX's earnings are expected to grow with 32.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.38%
EPS Next 3Y32.02%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IBRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNITYBIO INC

NASDAQ:IBRX (8/13/2025, 8:14:45 PM)

After market: 2.79 -0.03 (-1.06%)

2.82

+0.35 (+14.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-10 2025-11-10/amc
Inst Owners9.35%
Inst Owner Change3.42%
Ins Owners4.47%
Ins Owner Change0.54%
Market Cap2.49B
Analysts85.45
Price Target11.63 (312.41%)
Short Float %33.7%
Short Ratio8.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)20.5%
Min EPS beat(2)-14.89%
Max EPS beat(2)55.88%
EPS beat(4)2
Avg EPS beat(4)15.07%
Min EPS beat(4)-15.34%
Max EPS beat(4)55.88%
EPS beat(8)3
Avg EPS beat(8)-7.43%
EPS beat(12)5
Avg EPS beat(12)-7.93%
EPS beat(16)5
Avg EPS beat(16)-13.39%
Revenue beat(2)1
Avg Revenue beat(2)-2.08%
Min Revenue beat(2)-5.28%
Max Revenue beat(2)1.11%
Revenue beat(4)2
Avg Revenue beat(4)10.28%
Min Revenue beat(4)-59.26%
Max Revenue beat(4)104.56%
Revenue beat(8)6
Avg Revenue beat(8)103.18%
Revenue beat(12)10
Avg Revenue beat(12)228.26%
Revenue beat(16)13
Avg Revenue beat(16)344.73%
PT rev (1m)0%
PT rev (3m)1.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-658.62%
EPS NY rev (1m)0%
EPS NY rev (3m)6.53%
Revenue NQ rev (1m)5.96%
Revenue NQ rev (3m)-6.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 79.77
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.46
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0.04
BVpS-0.67
TBVpS-0.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -134.68%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.23%
FCFM N/A
ROA(3y)-112.85%
ROA(5y)-102.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.1%
Cap/Sales 21.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.22
Quick Ratio 2.05
Altman-Z -17.76
F-Score4
WACC10.71%
ROIC/WACCN/A
Cap/Depr(3y)249.59%
Cap/Depr(5y)199.51%
Cap/Sales(3y)15458.8%
Cap/Sales(5y)10051.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y21.08%
EPS Next 2Y21.38%
EPS Next 3Y32.02%
EPS Next 5Y38.62%
Revenue 1Y (TTM)2270.58%
Revenue growth 3Y151.22%
Revenue growth 5Y46.3%
Sales Q2Q%2423.88%
Revenue Next Year543.75%
Revenue Next 2Y309.55%
Revenue Next 3Y288.49%
Revenue Next 5Y140.93%
EBIT growth 1Y9.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.71%
OCF growth 3YN/A
OCF growth 5YN/A